Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Using routine blood parameters to anticipate clinical outcomes in invasive aspergillosis.

Pang L, Zhao X, Dickens BL, Lim JT, Cook AR, Netea MG, Donnelly JP, Herbrecht R, Johnson EM, Maertens JA, Kullberg BJ, Troke PF, Marr KA, Chai LYA.

Clin Microbiol Infect. 2019 Oct 24. pii: S1198-743X(19)30555-5. doi: 10.1016/j.cmi.2019.10.019. [Epub ahead of print]

PMID:
31669427
2.

Neutrophils differentially attenuate immune response to Aspergillus infection through complement receptor 3 and induction of myeloperoxidase.

Goh JG, Ravikumar S, Win MS, Cao Q, Tan AL, Lim JHJ, Leong W, Herbrecht R, Troke PF, Kullberg BJ, Netea MG, Chng WJ, Dan YY, Chai LYA.

Cell Microbiol. 2018 Mar;20(3). doi: 10.1111/cmi.12798. Epub 2017 Dec 20.

PMID:
29088499
3.

Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis.

Chai LY, Kullberg BJ, Earnest A, Johnson EM, Teerenstra S, Vonk AG, Schlamm HT, Herbrecht R, Netea MG, Troke PF.

PLoS One. 2014 Feb 28;9(2):e90176. doi: 10.1371/journal.pone.0090176. eCollection 2014.

4.

Tissue penetration of antifungal agents.

Felton T, Troke PF, Hope WW.

Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13. Review.

5.

Improvement in the outcome of invasive fusariosis in the last decade.

Nucci M, Marr KA, Vehreschild MJ, de Souza CA, Velasco E, Cappellano P, Carlesse F, Queiroz-Telles F, Sheppard DC, Kindo A, Cesaro S, Hamerschlak N, Solza C, Heinz WJ, Schaller M, Atalla A, Arikan-Akdagli S, Bertz H, Galvão Castro C Jr, Herbrecht R, Hoenigl M, Härter G, Hermansen NE, Josting A, Pagano L, Salles MJ, Mossad SB, Ogunc D, Pasqualotto AC, Araujo V, Troke PF, Lortholary O, Cornely OA, Anaissie E.

Clin Microbiol Infect. 2014 Jun;20(6):580-5. doi: 10.1111/1469-0691.12409. Epub 2013 Nov 18.

6.

An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity.

Chai LY, Netea MG, Tai BC, Khin LW, Vonk AG, Teo BW, Schlamm HT, Herbrecht R, Donnelly JP, Troke PF, Kullberg BJ.

J Antimicrob Chemother. 2013 Jul;68(7):1655-9. doi: 10.1093/jac/dkt055. Epub 2013 Apr 3.

PMID:
23557927
7.

Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis.

Chai LY, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, Vonk AG, Maertens J, Lortholary O, Donnelly PJ, Schlamm HT, Troke PF, Netea MG, Herbrecht R.

J Clin Microbiol. 2012 Jul;50(7):2330-6. doi: 10.1128/JCM.06513-11. Epub 2012 May 2.

8.

Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.

Troke PF, Hockey HP, Hope WW.

Antimicrob Agents Chemother. 2011 Oct;55(10):4782-8. doi: 10.1128/AAC.01083-10. Epub 2011 Jul 18. Erratum in: Antimicrob Agents Chemother. 2011 Nov;55(11):5415.

9.

The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis.

Schwartz S, Reisman A, Troke PF.

Infection. 2011 Jun;39(3):201-10. doi: 10.1007/s15010-011-0108-6. Epub 2011 Apr 22.

PMID:
21512792
10.

Early proinflammatory cytokines and C‐reactive protein trends as predictors of outcome in invasive Aspergillosis.

Chai L, Netea MG, Teerenstra S, Earnest A, Vonk AG, Schlamm HT, Herbrecht R, Troke PF, Kullberg BJ.

J Infect Dis. 2010 Nov 1;202(9):1454-62. doi: 10.1086/656527.

PMID:
20879853
11.

Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.

Brüggemann RJ, Blijlevens NM, Burger DM, Franke B, Troke PF, Donnelly JP.

J Antimicrob Chemother. 2010 Jan;65(1):107-13. doi: 10.1093/jac/dkp416.

PMID:
19933691
12.

Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients.

Lambourne J, Agranoff D, Herbrecht R, Troke PF, Buchbinder A, Willis F, Letscher-Bru V, Agrawal S, Doffman S, Johnson E, White PL, Barnes RA, Griffin G, Lindsay JA, Harrison TS.

Clin Infect Dis. 2009 Nov 15;49(10):1486-91. doi: 10.1086/644619.

PMID:
19827955
13.

Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign.

Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, Troke PF, Denning DW, Bennett JE, de Pauw BE, Rubin RH.

Clin Infect Dis. 2007 Feb 1;44(3):373-9. Epub 2006 Dec 29.

PMID:
17205443
14.

Safety of voriconazole and dose individualization.

Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND.

Clin Infect Dis. 2003 Apr 15;36(8):1087-8. No abstract available.

PMID:
12684928
15.

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.

N Engl J Med. 2002 Aug 8;347(6):408-15.

16.

Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS.

Hegener P, Troke PF, Fätkenheuer G, Diehl V, Ruhnke M.

AIDS. 1998 Nov 12;12(16):2227-8. No abstract available.

PMID:
9833866
18.

Fluconazole: its properties and efficacy in vaginal candidiasis.

Troke PF.

Curr Probl Dermatol. 1996;24:203-8. Review. No abstract available.

PMID:
8743271
19.

Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B.

Sugar AM, Hitchcock CA, Troke PF, Picard M.

Antimicrob Agents Chemother. 1995 Mar;39(3):598-601.

20.

Fluconazole-insensitive OPC in AIDS patients.

Troke PF, Hitchcock CA.

J Infect. 1994 Mar;28(2):223-7. No abstract available.

PMID:
8080544
21.

Fluconazole resistance in Candida glabrata.

Hitchcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW.

Antimicrob Agents Chemother. 1993 Sep;37(9):1962-5.

22.

Standardized susceptibility testing of fluconazole: an international collaborative study.

Pfaller MA, Dupont B, Kobayashi GS, Müller J, Rinaldi MG, Espinel-Ingroff A, Shadomy S, Troke PF, Walsh TJ, Warnock DW.

Antimicrob Agents Chemother. 1992 Sep;36(9):1805-9.

23.

Fluconazole and other azoles: translation of in vitro activity to in vivo and clinical efficacy.

Troke PF, Andrews RJ, Pye GW, Richardson K.

Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S276-80. Review.

PMID:
2184505
24.

Discovery of fluconazole, a novel antifungal agent.

Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ.

Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S267-71. Review.

PMID:
2184503
25.
26.

Interaction of microsomal cytochrome P-450 isolated from Aspergillus fumigatus with fluconazole and itraconazole.

Ballard SA, Kelly SL, Ellis SW, Troke PF.

J Med Vet Mycol. 1990;28(4):327-34.

PMID:
2176687
27.

In vitro potency and in vivo activity of azoles.

Troke PF, Marriott MS, Richardson K, Tarbit MH.

Ann N Y Acad Sci. 1988;544:284-93. No abstract available.

PMID:
3063173
28.

Design and evaluation of a systemically active agent, fluconazole.

Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ.

Ann N Y Acad Sci. 1988;544:4-11. No abstract available.

PMID:
2850752
29.

Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.

Troke PF, Andrews RJ, Marriott MS, Richardson K.

J Antimicrob Chemother. 1987 May;19(5):663-70.

PMID:
3038824
30.
31.

Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.

Troke PF, Andrews RJ, Brammer KW, Marriott MS, Richardson K.

Antimicrob Agents Chemother. 1985 Dec;28(6):815-8.

32.

Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

Richardson K, Brammer KW, Marriott MS, Troke PF.

Antimicrob Agents Chemother. 1985 May;27(5):832-5.

33.

Mechanism of action of nikkomycin and the peptide transport system of Candida albicans.

McCarthy PJ, Troke PF, Gull K.

J Gen Microbiol. 1985 Apr;131(4):775-80.

PMID:
3886837
34.

Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans.

Ryder NS, Seidl G, Troke PF.

Antimicrob Agents Chemother. 1984 Apr;25(4):483-7.

Supplemental Content

Loading ...
Support Center